Recurrent glioblastoma of childhood treated with bevacizumab: Case report and molecular features

Child's Nervous System

Volumn 26, Issue 1, 2010, Pages 137-143

  Zhang, Wei ^a   Lin, Yi ^a   Chen, Baoshi ^a   Song, Sonya Wei ^b   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Childhood; Glioblastoma multiforme; Molecular genetics; Targeted therapy

Indexed keywords

BEVACIZUMAB; GELATINASE B; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN KINASE B; RAS PROTEIN; TEMOZOLOMIDE; TOPOTECAN; VASCULOTROPIN;

ADOLESCENT; ANTIGEN EXPRESSION; ARM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CHILDHOOD CANCER; GLIOBLASTOMA; HEADACHE; HUMAN; LEG; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTOSIS; RECURRENT CANCER; SPEECH DISORDER; TREATMENT RESPONSE; TUMOR BIOPSY; WEAKNESS;

ADOLESCENT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; DACARBAZINE; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 71349086577     PISSN: 02567040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00381-009-0995-3     Document Type: Article

References (14)

1. CH Rickert W Paulus 2001 Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification Childs Nerv Syst 17 503 511 10.1007/s003810100496 1:STN:280:DC%2BD3MrjvVemuw%3D%3D 11585322 (Pubitemid 32842704)
2. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
3. WK Yung RE Albright J Olson R Fredericks K Fink MD Prados M Brada A Spence RJ Hohl W Shapiro M Glantz H Greenberg RG Selker NA Vick R Rampling H Friedman P Phillips J Bruner N Yue D Osoba S Zaknoen VA Levin 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593 10.1054/bjoc.2000.1316 1:CAS:528:DC%2BD3cXmvVCgsrs%3D 10944597 (Pubitemid 30636298)
4. JJ Vredenburgh A Desjardins JE Herndon 2nd JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas Clin Cancer Res 13 1253 1259 10.1158/1078-0432.CCR-06-2309 1:CAS:528:DC%2BD2sXhvF2htr8%3D 17317837 (Pubitemid 46424067)
5. R Schröder KD Feisel RI Ernestus 2002 Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas J Neuro-Oncol 56 127 132 10.1023/A:1014527929948 (Pubitemid 34272303)
6. A Pagenstecher EM Wussler G Opdenakker B Volk IL Campbell 2001 Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors J Neuropathol Exp Neurol 60 598 612 1:CAS:528:DC%2BD3MXltVOhsrk%3D 11398836
7. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 10.1056/NEJM200011093431901 1:CAS:528:DC%2BD3cXosFOltLg%3D 11070098 (Pubitemid 30826035)
8. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 10.1056/NEJMoa043331 1:CAS:528: DC%2BD2MXit1Wktro%3D 15758010 (Pubitemid 40349502)
9. MA Cobleigh VK Langmuir GW Sledge KD Miller L Haney WF Novotny JD Reimann A Vassel 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 117 124 10.1053/j.seminoncol. 2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF 14613032
10. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D 12890841 (Pubitemid 36910021)
11. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
12. H Ohgaki P Kleihues 2007 Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 1445 1453 10.2353/ajpath.2007.070011 1:CAS:528:DC%2BD2sXlvFCns74%3D 17456751 (Pubitemid 47339290)
13. T Pietsch MD Taylor JT Rutka 2004 Molecular pathogenesis of childhood brain tumors J Neuro-Oncol 70 203 215 10.1007/s11060-004-2750-7 (Pubitemid 39545732)
14. M Nakamura K Shimada E Ishida T Higuchi H Nakase T Sakaki N Konishi 2007 Molecular pathogenesis of pediatric astrocytic tumors Neuro Oncol 9 113 123 10.1215/15228517-2006-036 1:CAS:528:DC%2BD2sXltFWgsb8%3D 17327574 (Pubitemid 46580313)